Lipid X, a precursor of lipid A (the toxic moiety of endotoxin), has been shown to protect animals from the lethal effects of endotoxin challenge. We investigated the mechanism of action of lipid X and 3-aza-lipid X, a diamino-analogue, in vitro, using the ability of lipopolysaccharide (LPS) to prime neutrophils for an enhanced release of toxic oxygen radicals. Lipid X and 3-aza-lipid X inhibited LPS-induced neutrophil priming in a concentration-dependent manner. At high concentrations, 3-aza-lipid X was a partial agonist of priming. Lipid X was found to inhibit LPS-induced priming by directly interacting with the neutrophil in contrast to polymyxin B, which neutralized LPS by binding to it. Increasing concentrations of lipid X shifted the LPS dose response curve of neutrophils rightward but did not prevent maximum priming at higher LPS concentrations, a finding consistent with competitive inhibition. These results suggest that lipid X, a compound structurally related to lipid A, may block neutrophil priming by competing with LPS for cellular binding sites. Lipid X appears to have a novel mechanism of inhibiting LPS effect and may have efficacy in the treatment of gram-negative sepsis.
Introduction
Septic shock caused by gram-negative bacteria has a high mortality despite appropriate antibiotics and modern critical care support (1-4). Endotoxin, a lipopolysaccharide associated with the outer membrane of gram-negative bacteria, has been implicated in the pathogenesis of this often fatal syndrome (5) (6) (7) . Because of the presumed role of endotoxin in septic shock, investigators have studied therapeutic interventions aimed at alleviating the effects of endotoxin or its secondary mediators. Corticosteroids, naloxone, cyclooxygenase inhibitors, endotoxin inhibitors (polymyxin B), and anti-core endotoxin antibodies have been investigated, but their use and efficacy in human septic shock remain controversial (8) (9) (10) (11) (12) (13) (14) (15) (16) .
Recently, novel glucosamine-derived phospholipids related to lipid A, the toxic moiety of endotoxin, have been identified from mutant Escherichia coli (17) (18) (19) and chemically synthesized (20, 21) . Lipid X (2,3 diacyl glucosamine 1-phosphate), the prototype, is a monosaccharide precursor in the biosynthetic pathway of lipid A (22, 23) . Lipid X has some of the immunomodulating properties of endotoxin (24) (25) (26) but is much less toxic (18, 27 ). This compound has been shown to protect mice and sheep from the lethality of endotoxin administration, though the mechanism ofthis protective effect is unknown (27) (28) (29) . The structural similarity between lipid X and lipid A suggests that lipid X might be mediating its protective effect by specifically blocking endotoxin-triggered events, and possibly even competing directly with LPS' for cellular binding sites, a hypothesis that can be tested in an in vitro system. LPS has been reported to "prime" neutrophils, resulting in a markedly enhanced respiratory burst when stimulated with a variety of activators (30) . In the present study, lipid X and its diamino analog, 3-aza-lipid X, were evaluated for their ability either to prime or to prevent LPS-mediated priming ofhuman neutrophils. We report here that lipid X can prevent neutrophil priming by LPS in a concentration-dependent manner and that 3-aza-lipid X appears to be a partial agonist of neutrophil priming. Furthermore, lipid X shifts the LPS dose response curve of neutrophils to the right, suggesting that lipid X may be a competitive inhibitor of LPS-induced priming. This class of compounds appears to have a unique anti-endotoxin effect which may have therapeutic efficacy in the treatment of septic shock and offers a novel approach to the management of this highly lethal disorder.
Methods
Endotoxin, lipidX and 3-aza-lipid X. Highly purified protein-free LPS extracted from the Salmonella minnesota Re595 mutant and Salmonella typhimurium (List Biological Laboratories, Campbell, CA) was prepared as a stock solution (I mg/ml) in sterile pyrogen-free water sonicated for 4 min at maximum output (model 16-850, Virtis Co., Gardiner, NY), and then stored in small aliquots at -70'C. On the day of use the LPS was thawed, sonicated for an additional 2 min, and adjusted to the desired final concentration in Hanks' balanced salt solution (HBSS; Gibco, Grand Island, New York) without calcium and magnesium (-).
Lipid X (2,3 diacyl glucosamine 1-phosphate) and 3-aza-lipid X (2,3 diacyl diaminoglucose 1-phosphate) were supplied as crystaline di-Tris salts by Sandoz Forschungsinstitut, Vienna, Austria (Fig. 1 ).
These compounds were dissolved, sonicated, stored, and prepared for use in an identical fashion to the LPS.
1. Abbreviations used in this paper: FMLP, N-formyl-methionyl-leucyl-phenylalanine; k112, concentration of LPS in ng/ml resulting in a half-maximal priming effect; LPS, lipopolysaccharide. The peak absorption change and the absorption change per minute were converted to nanomoles of cytochrome c reduced, using the extinction coefficient of 2.1 X 104 M-' CM-' previously reported (35) and expressed as nanomoles O°/106 neutrophils (total production) and nanomoles O°/106 neutrophils per minute (rate of production), respectively. Some specimens were stimulated in the presence of superoxide dismutase 10 Ag/ml, to ascertain that the absorption changes measured were due specifically to°2 release. The activity of the Salmonella typhimurium LPS (smooth parent strain) was confirmed in the priming assay, but the Salmonella minnesota Re595 LPS (core endotoxin) was used in the subsequent experiments reported here.
Effect of lipid X, 3-aza-lipid X, and polymyxin B on neutrophil priming. Lipid X and 3-aza-lipid X were added to the cell suspension at room temperature 15 min before initiation of incubation with LPS unless specified otherwise. Polymyxin B (Upjohn Co., Kalamazoo, MI) was reconstituted from powder to the desired concentration in HBSS(-) on the day of use. Neutrophils incubated with lipid X, 3-aza-lipid X, or polymyxin B did not differ in°2 release from cells incubated in buffer alone upon stimulation with either FMLP or phorbol-myristate-acetate (PMA; Sigma Chemical Co.; 500 ng/ml). Statistics. Means are expressed plus or minus the standard error of the mean (SEM) in the text and figures where applicable. Differences between experimental groups were analyzed using paired and unpaired Student t tests where indicated. Data trends were analyzed with the Mann test for trend (36) or the Bartholomew test (37) as stated.
Results
We initially confirmed previous observations showing that LPS enhances the O2 production of neutrophils exposed to FMLP (30) . In 10 paired experiments, neutrophils from different donors incubated with LPS (10 ng/ml) for 60 min followed by activation with FMLP released 18.16±2.57 nmol°2 /l06 neutrophils compared with 3.20±0.63 nmol°2/106 neutrophils when cells were incubated in pyrogen-free buffer alone (mean±SEM; P < 0.005). Also, as previously reported, LPS priming of neutrophils was noted to augment both total°2 production and rate of O2 production by stimulated cells. Except where indicated, the data reported here are expressed as the total amount of°2 released. The generation of O2 by neutrophils was dependent on the concentration of LPS (Fig. 2) . LPS at 1 ,ug/ml caused a small but significant (paired Student's t test; P < 0.05) decrease in O2 production from the peak level and an insignificant fall in neutrophil viability, as determined by trypan blue exclusion.
Lipid X, in contrast, had no effect on FMLP-stimulated O2 release from neutrophils, even at concentrations as high as 1 ug/ml (Fig. 2 ). Neutrophils incubated with this concentration of lipid X were identical to control cells exposed only to pyrogen-free buffer in respect to clumping, viability, and PMA stimulated O2 release. Lipid X could not be evaluated at levels > 2 ,gg/ml because of clumping of cells at these higher concentrations. This clumping was considered nonspecific because addition of lipid X (> 2 ,ug/ml) to neutrophils in an aggregometer at 370C resulted in a slow increase in light transmittance over 60 min and not a typical stimulated aggregation response as characteristically seen with a variety of activators such as PMA or C5a. Control neutrophils and those exposed to lower lipid X concentrations (< 2 Atg/ml) did not show clumping by microscopic examination or aggregometry.
In separate paired experiments, lipid X, at a concentration achievable in vivo (27) was tested in the priming assay. Again, lipid X alone (1 gg/ml) had no effect on the neutrophil respiratory burst, but cells incubated with LPS (10 ng/ml) produced significantly (P < 0.005) more O2 than either the buffer or lipid X exposed cells (Table I ). In contrast, incubation of neu- trophils with both lipid X (1 ,ug/ml) and LPS (10 ng/ml) resulted in a profound (P < 0.005) inhibition of O2 release when compared with cells treated with LPS alone (Table I) . Next, the concentration dependence of this blocking effect of lipid X on LPS-induced neutrophil priming was examined. Lipid X in concentrations from 100 ng/ml to 2 jg/ml was added to neutrophils 15 min before the start ofincubation with LPS (10 ng/ml). As can be seen in Fig. 3 , lipid X prevented LPS from priming neutrophils in a concentration-dependent manner with nearly complete inhibition at 2 ,gg/ml. Fig. 4 shows the temporal relationship between the addition of lipid X and its ability to inhibit LPS-induced neutrophil priming. Again, lipid X (1 gg/ml) significantly prevented the enhanced FMLP-stimulated O2 release seen with cells exposed to LPS alone when added 15 min before the start of incubation. As lipid X was added later and later (after neutrophil exposure to LPS), its ability to prevent priming was diminished, but significant (P < 0.05) inhibition of priming was 18- . 16 LPS Lipid X (ng/ml) Figure 3 . The effect of increasing concentrations of lipid X on LPSinduced neutrophil priming. Neutrophils were pre-exposed to lipid X for 15 Paired experiments comparing 3-aza-lipid X with lipid X revealed a similar concentration-dependent inhibition of LPSinduced neutrophil priming, though 3-aza-lipid X was slightly less potent on a weight basis (data not shown). Unlike lipid X, 3-aza-lipid X did not cause neutrophil clumping at concentrations up to 10 ,ug/ml. Further studies at these high concentrations showed 3-aza-lipid X to have an apparent priming effect of its own (Fig. 5) . In these experiments, 3-aza-lipid X augmented O2 release by neutrophils at concentrations > 2 ug/ml with and without the presence of LPS. At lower concentrations, 3-aza-lipid X significantly inhibited LPS-induced priming of neutrophils, but this was only a partial effect. Temporal relationship between the addition of lipid X and its ability to prevent LPS-induced neutrophil priming. Neutrophils were incubated for 60 min at 370C with LPS (10 ng/ml). Lipid X (1 ug/ml) was added to the neutrophil-LPS incubation at the time points indicated along the abscissa and O2 production was determined.
Dashed lines are as described for Fig. 3 . Lipid X added as late as 30 min into the incubation with LPS significantly (P < 0.05) inhibited priming.
To further evaluate the mechanism of inhibition of priming by these compounds, the activity of lipid X was compared with that of polymyxin B, a well-characterized inhibitor of endotoxin known to neutralize LPS by binding tightly to it (38) . In these experiments (Fig. 6 A) neutrophils were first exposed to either lipid X (2 ,gg/ml) or polymyxin B (1 j.g/ml)
for 30 pletely blocked the priming effect, even though the neutrophils were washed and resuspended in buffer containing only LPS. In contrast, the polymyxin B-treated neutrophils, processed in an identical fashion, still demonstrated significant priming (42%). Next, the possibility that these inhibitors might be interacting directly with LPS to exert their anti-priming effect was investigated. Lipid X or polymyxin B (Fig. 6 B) were combined with LPS for 30 min before both were added to the neutrophil incubation. Polymyxin B, known to bind tightly to LPS, completely prevented priming, whereas lipid X only partially inhibited priming when allowed to interact directly with LPS before neutrophil incubation. Therefore it appeared that in contrast to polymyxin B, the blocking of LPS-induced priming by lipid X was primarily due to a direct interaction with the neutrophil and not LPS.
Because many LPS interactions with cell membranes are nonspecific, of high affinity, and neither saturable nor competitive (39), it was necessary to better clarify the nature of the inhibitory effect of lipid X on LPS-induced neutrophil priming. To test the reversibility and specificity of this blocking effect, experiments were conducted to see if higher concentrations of LPS could overcome the inhibitory action of lipid X over a wide dose range. Serial LPS dose response curves were done in the presence ofincreasing concentrations of lipid X (0, 200, 400, and 800 ng/ml) and the data expressed as the initial rate of 02 production (nanomoles 0°/106 neutrophils per minute). Lipid X shifted the LPS dose response curve to the right, but the maximal priming effect could still be achieved by higher concentrations of LPS (Fig. 7, representative experiment) . The concentration of LPS (ng/ml) required to produce a half-maximal priming response (ki/2) was calculated for each ofthe lipid X doses in three experiments (Table II) . The k1/2 for LPS-induced neutrophil priming progressively increased with increasing concentrations of Lipid X: 0.62±0.10, 1.03±0.1 1, 1.23±0.08, and 3.94±0.61, respectively (mean±SEM; P < 0.001).
Discussion
Lipid X, a monosaccharide precursor of lipid A (17) (18) (19) , has been shown to protect animals from the lethality of LPS (27-29) but the mechanism of this protective action is unknown. The structural similarity between lipid X and lipid A, the toxic component of LPS, suggested that the therapeutic action of lipid X might involve the direct inhibition of LPStriggered cellular effects. In this investigation, we have used neutrophil priming by LPS, a recently described functional (40) and in the range of endotoxin concentrations found in blood of patients with septic shock (41, 42) . Priming is evident with 10-12 M concentrations of LPS, suggestive of a high-affinity interaction. Other direct cellular effects of LPS seen in this dose range include the stimulation of monocytes to produce both cachectin (43) and interleukin 1 (44) , endogenous molecules known to be important secondary mediators of the in vivo actions of endotoxin (45, 46). Neutrophil activation during sepsis has been linked to tissue injury and the development of multiorgan failure, one of the major causes of death in human septic shock (47) . The ability of LPS to prime neutrophils for an enhanced respiratory burst may represent an in vitro correlate ofthis toxic component of sepsis (30, 48) .
Work by Guthrie et al. has shown that priming is not blocked by cyclohexamide, an inhibitor of protein synthesis, and does not appear to be due to a change in the number or affinity of FMLP binding sites when determined at 40C (30) . Further, priming of neutrophils by LPS was temperature-dependent and appeared to proceed in at least two steps. Neutrophils exposed briefly to LPS at 370C, washed, and resuspended in fresh pyrogen-free buffer could still become primed with subsequent incubation at 370 even though the LPS concentration was reduced below that required for priming. This suggests that attachment of LPS to the cell membrane is rapid, but a subsequent time-and temperature-dependent event is then required for priming to occur. These conditions are highly reminescent of work examining LPS binding to rabbit erythrocytes and platelets (49) (50) (51) . In those experiments, LPS attached to cell membranes very rapidly, even at 40C, followed by insertion of the LPS molecule into the lipid bilayer, a timeand temperature-dependent step (30-60 min at 370C). Recently, it has been shown that neutrophils contain acyloxyacyl hydrolases that can selectively remove nonhydroxylated acyl chains from lipid A (52) . As the intracellular handling of LPS becomes better understood, it may be found that the metabolism of LPS and related compounds plays a role in either priming or inhibition of priming.
LPS has also been shown to cause the myristoylation of specific macrophage proteins over a brief time period of min, and it has been suggested that myristoylation of proteins may represent an early event in both signal transduction and the priming of macrophages by LPS for an enhanced stimulated release of 20:4 arachidonic acid metabolites (53) . The time course of protein myristoylation and the similarities between LPS-induced neutrophil and macrophage priming suggest that these processes may be related. Although the mechanism of LPS-induced neutrophil priming is unknown, the current data does not eliminate the possibility that LPS is directly affecting the phosphatidyl-inositol-transmembrane signal pathway (signal transduction) involved in generating the respiratory burst via FMLP (30) . If correct, this may have broad implications because many diverse cell types utilize this signal pathway (54, 55) .
The inhibition of LPS-induced neutrophil priming by lipid X, a compound that is structurally very similar to halfof the lipid A molecule, supports the concept that lipid X may be directly antagonizing the action of LPS on neutrophils by interacting with the same cellular site(s) mediating this effect. Lipid X was shown to exert its major anti-LPS effect by interacting directly with the neutrophil, unlike polymyxin B which appears to produce much ofits effect by "neutralizing"' LPS by binding tightly to the LPS molecule. Further, 3-azalipid X, the diamino analog of lipid X, displays inhibitory effects at low concentrations identical to lipid X but LPS-like (agonist) activity at higher concentrations. The demonstration of both agonist and antagonist effect by the same molecule, chemically related to LPS, suggests the possibility that a receptor-ligand interaction may be important in producing neutrophil priming.
Lipid X, in increasing concentrations, shifts the LPS dose response curve of human neutrophils rightward, necessitating higher concentrations of LPS to achieve the same rate of O2
release. This pattern of response to a blocking agent is consistent with competitive inhibition, though a role for effects on membrane fluidity and permeability have not been completely ruled out. In addition, the respiratory burst represents a complex cascade in which multiple binding sites with more than one type of interaction could be present. The possibility also remains that lipid X or a metabolite oflipid X may be effecting a step in cell activation removed from the major site of LPS action, although it does not appear to influence O2 production in the absence of LPS.
These experiments provide evidence that LPS-induced neutrophil priming may be caused by the specific binding of LPS to cell component(s) or receptor(s) involved in the regulation ofthe respiratory burst, and that structurally similar molecules may be able to compete with LPS for these putative site(s) resulting in a unique anti-LPS effect. Regardless of the exact mechanism(s) of this action, lipid X is representative of a group of compounds with novel properties that may be useful in the treatment of gram-negative sepsis and septic shock. Further, lipid X and its analogs can be utilized to probe the molecular basis of the cellular actions of LPS and provide a more complete understanding ofthe pathogenesis ofthe septic shock syndrome.
